Eli Lilly’s stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its rising valuation.
Communicating your story to the Street
Eli Lilly’s stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its rising valuation.